Impact of FDG PET in Optimizing Patient Selection for Cytoreductive Surgery in Recurrent Ovarian Cancer

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2013 Nov 14

PMID 24221243

Citations 11

Authors

Yasuhiko Ebina

Hidemichi Watari

Masanori Kaneuchi

Mahito Takeda

Masayoshi Hosaka

Masataka Kudo

Hideto Yamada

Noriaki Sakuragi

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the impact of PET and PET/CT scanning on decision-making in management planning and to identify the optimal setting for selecting candidates for surgery in suspicious recurrent ovarian cancer.

Methods: A retrospective chart review was performed in patients with possible recurrent ovarian cancer after primary optimal cytoreduction and taxane/carboplatin chemotherapy who had undergone FDG PET or FDG PET/CT scans from July 2002 to August 2008 to help make treatment decisions. The analysis included 44 patients who had undergone a total of 89 PET scans. The positive PET scans were classified as follows. (1) localized (one or two localized sites of FDG uptake), (2) multiple (three or more sites of FDG uptake), (3) diffuse (extensive low-grade activity outlining serosal and peritoneal surfaces).

Results: Of the 89 PET scans, 52 (58.4%) led to a change in management plan. The total number of patients in whom cytoreductive surgery was selected as the treatment of choice increased from 12 to 35. Miliary disseminated disease, which was not detected by PET scan, was found in 22.2% of those receiving surgery. Miliary disseminated disease was detected in 6 of the 12 patients with recurrent disease whose treatment-free interval (TFI) was <12 months, whereas none of those with a TFI of ≥12 months had such disease (P = 0.0031).

Conclusion: PET or PET/CT is useful for selecting candidates for cytoreductive surgery among patients with recurrent ovarian cancer. To avoid surgical attempts in those with miliary dissemination, patients with a TFI of ≥12 months are the best candidates for cytoreductive surgery.

Citing Articles

18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature.

Allahqoli L, Hakimi S, Lagana A, Momenimovahed Z, Mazidimoradi A, Rahmani A J Imaging. 2023; 9(10).

PMID: 37888330 PMC: 10607780. DOI: 10.3390/jimaging9100223.

EANM guideline on the role of 2-[F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular....

Delgado Bolton R, Aide N, Colletti P, Ferrero A, Paez D, Skanjeti A Eur J Nucl Med Mol Imaging. 2021; 48(10):3286-3302.

PMID: 34215923 DOI: 10.1007/s00259-021-05450-9.

Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Virarkar M, Ganeshan D, Gulati A, Palmquist S, Iyer R, Bhosale P Abdom Radiol (NY). 2020; 46(6):2323-2349.

PMID: 33175199 DOI: 10.1007/s00261-020-02847-2.

Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers.

Tsoi T, Chiu K, Chu M, Ngan H, Lee E J Ovarian Res. 2020; 13(1):61.

PMID: 32434520 PMC: 7238625. DOI: 10.1186/s13048-020-00662-3.

Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.

Palomar Munoz A, Cordero Garcia J, Talavera Rubio M, Garcia Vicente A, Pena Pardo F, Jimenez Londono G Medicine (Baltimore). 2018; 97(17):e0098.

PMID: 29702969 PMC: 5944512. DOI: 10.1097/MD.0000000000010098.

References

Fulham M, Carter J, Baldey A, Hicks R, Ramshaw J, Gibson M . The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol. 2009; 112(3):462-8. DOI: 10.1016/j.ygyno.2008.08.027. View

Sebastian S, Lee S, Horowitz N, Scott J, Fischman A, Simeone J . PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging. 2007; 33(1):112-8. DOI: 10.1007/s00261-007-9218-0. View

Bristow R, Puri I, Chi D . Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2008; 112(1):265-74. DOI: 10.1016/j.ygyno.2008.08.033. View

Rustin G, van der Burg M, Griffin C, Guthrie D, Lamont A, Jayson G . Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010; 376(9747):1155-63. DOI: 10.1016/S0140-6736(10)61268-8. View

Ferrozzi F, Bova D, De Chiara F, Garlaschi G, Draghi F, COCCONI G . Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history. Clin Imaging. 1998; 22(5):364-70. DOI: 10.1016/s0899-7071(98)00023-0. View

Palomar A, Nanni C, Castellucci P, Ambrosini V, Montini G, Allegri V . Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Mol Imaging Biol. 2011; 14(1):123-9. DOI: 10.1007/s11307-010-0468-9. View

Hising C, Anjegard I, Einhorn N . Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients. Am J Clin Oncol. 1991; 14(2):111-4. DOI: 10.1097/00000421-199104000-00003. View

Rose P, Faulhaber P, Miraldi F, Abdul-Karim F . Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol. 2001; 82(1):17-21. DOI: 10.1006/gyno.2001.6246. View

Garcia-Velloso M, Jurado M, Ceamanos C, Aramendia J, Garrastachu M, Lopez-Garcia G . Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging. 2007; 34(9):1396-405. DOI: 10.1007/s00259-007-0366-9. View

10.

Tanner E, Chi D, Eisenhauer E, Diaz-Montes T, Santillan A, Bristow R . Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?. Gynecol Oncol. 2010; 117(2):336-40. DOI: 10.1016/j.ygyno.2010.01.014. View

11.

Limei Z, Yong C, Yan X, Shuai T, Jiangyan X, Zhiqing L . Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. Int J Gynecol Cancer. 2013; 23(4):598-607. DOI: 10.1097/IGC.0b013e31828a183c. View

12.

Soussan M, Wartski M, Cherel P, Fourme E, Goupil A, Le Stanc E . Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol. 2007; 108(1):160-5. DOI: 10.1016/j.ygyno.2007.07.082. View

13.

Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks R . The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol. 2006; 103(1):271-6. DOI: 10.1016/j.ygyno.2006.03.004. View

14.

Salani R, Santillan A, Zahurak M, Giuntoli 2nd R, Gardner G, Armstrong D . Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007; 109(4):685-91. DOI: 10.1002/cncr.22447. View

15.

Rustin G, Nelstrop A, Tuxen M, Lambert H . Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996; 7(4):361-4. DOI: 10.1093/oxfordjournals.annonc.a010602. View

16.

Mangili G, Picchio M, Sironi S, Vigano R, Rabaiotti E, Bornaghi D . Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging. 2006; 34(5):658-666. DOI: 10.1007/s00259-006-0306-0. View

17.

Chi D, McCaughty K, Diaz J, Huh J, Schwabenbauer S, Hummer A . Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006; 106(9):1933-9. DOI: 10.1002/cncr.21845. View

18.

Zanaboni F, PRESTI M, Scarfone G, Bolis G . CA 125 reliability in predicting ovarian cancer recurrence. Tumori. 1989; 75(1):69-71. DOI: 10.1177/030089168907500118. View

19.

Shih K, Chi D, Barakat R, Leitao Jr M . Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol. 2010; 117(2):330-5. DOI: 10.1016/j.ygyno.2010.01.046. View